Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Aumolertinib
2. Hs-10296
3. N-(5-((4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl)amino)-2-(2-(dimethylamino)ethyl-methylamino)-4-methoxyphenyl)prop-2-enamide
1. Hs-10296
2. 1899921-05-1
3. Aumolertinib
4. Ameile
5. Aumolertinib [usan]
6. Hs-10297
7. Egfr T790m Inhibitor Hs-10296
8. Chembl4761468
9. T4rs462g19
10. N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide
11. 2-propenamide, N-(5-((4-(1-cyclopropyl-1h-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-
12. N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide
13. Aumolertinib [inn]
14. Almonertinib [who-dd]
15. Unii-t4rs462g19
16. Schembl17683063
17. Gtpl11136
18. Eq143
19. Ex-a3721
20. Zad92105
21. Hs 10296 [who-dd]
22. Bdbm50557548
23. Eq-143
24. S8817
25. Who 11295
26. At30756
27. Hs10296
28. As-84436
29. Example 26 [wo2016054987a1]
30. Hs-10206
31. Hy-112823
32. Cs-0066162
| Molecular Weight | 525.6 g/mol |
|---|---|
| Molecular Formula | C30H35N7O2 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 11 |
| Exact Mass | 525.28522338 g/mol |
| Monoisotopic Mass | 525.28522338 g/mol |
| Topological Polar Surface Area | 87.6 Ų |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 823 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Almonertinib inhibits EGFR tyrosine kinase targeting EGFR-sensitizing and T790M resistance mutations.
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATES SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
A Aumolertinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aumolertinib, including repackagers and relabelers. The FDA regulates Aumolertinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aumolertinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Aumolertinib supplier is an individual or a company that provides Aumolertinib active pharmaceutical ingredient (API) or Aumolertinib finished formulations upon request. The Aumolertinib suppliers may include Aumolertinib API manufacturers, exporters, distributors and traders.
Aumolertinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aumolertinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aumolertinib GMP manufacturer or Aumolertinib GMP API supplier for your needs.
A Aumolertinib CoA (Certificate of Analysis) is a formal document that attests to Aumolertinib's compliance with Aumolertinib specifications and serves as a tool for batch-level quality control.
Aumolertinib CoA mostly includes findings from lab analyses of a specific batch. For each Aumolertinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aumolertinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Aumolertinib EP), Aumolertinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aumolertinib USP).
LOOKING FOR A SUPPLIER?
